Weight loss drugs can reduce symptoms of Hidradenitis Suppurativa hiding place, discover the study

It has been shown that weight loss and diabetes drugs from GLP-1, such as Ozempique and Wegovy, reduce the symptoms of a painful skin condition.

The Suppurativa Imaudanitis, also known as the Inverted Acne, is an affection that makes small painful pieces develop under the skin, according to Mayo Clinic.

These lumps generally develop in the areas of the body where the skin rubs and can be recurrent.

Popular weight loss drugs could relieve the painful symptoms of arthritis, report doctors

Suppurativa hidradenitis tends to start after puberty and before the age of 40, persisting for many years and potentially worsen over time, according to Mayo Clinic. Women are three times more likely to develop the condition.

Medical and surgical therapy can help manage the state and prevent complications.

GLP-1 drugs could improve certain skin conditions, according to experts. (istock)

A new study, published in the journal Jama Dermatology, analyzed how the drug GLP-1 could have an impact on this skin condition.

French researchers noted that Suppurativa hidradenitis is generally associated with overweight and obesity, affecting 50% of these patients.

Who should take weight loss medication? Doctors share the best candidates

Experts have noted that weight loss, whether through the diet or obesity surgery, has a “beneficial effect” on the skin of the skin for most patients.

As GLP-1s have demonstrated a “major efficiency” in weight loss, researchers have hypothesized that drugs could also have anti-inflammatory properties that could help symptoms of the skin.

Researchers have found that patients with obesity and diabetes experienced a reduction in symptoms when taking a GLP-1. (istock)

The study evaluated 66 patients with Suppurativa Hidradenitis who took a GLP-1 medication, following an average of 18.5 months later.

Almost 90% of study participants suffered from diabetes and their average BMI was 39.4. Treatment of the skin condition was initiated for 53% of patients.

Does Ozempic ruin your teeth? That knowing about the impact on dental health

After six months, 54% of patients had a reduction in symptoms.

At the last consultation, 67% of participants declared discounts and 60% decreased pain.

Suppurativa hidradenitis, shown here, generally occurs before the age of 40 and can worsen over time. (istock)

‘Prudent optimism’

Dr. Brendan Camp, dermatologist in New York, reacted to these results of the study with “careful optimism”.

“It is impressive that, on a median of 18.5 months of follow-up, the agonists of the GLP-1 receptors led to significant reductions in the severity of the HS, eruptions and pain in patients, most of which were obese and suffered from diabetes,” he said in an interview with Fox News Digital.

Click here to register for our Health Newsletter

Camp has confirmed how weight loss assisted by GLP-1 can reduce “mechanical friction” and “adipose-directed inflammation in sensitive areas” where skin conditions can occur.

GLP-1s also seem to have anti-inflammatory effects, which could potentially improve skin healing and reduce the frequency of inflammatory rashes in skin diseases, he said.

A dermatologist said that he did not currently recommend GLP-1 only for HS or other skin conditions, because it is not prescribed for this indication. (istock)

Potential limitations

Camp stressed that if the study represents a “promising therapeutic signal”, its retrospective conception “limits causal conclusions”.

“Solid confirmation via randomized clinical trials is essentially necessary,” he said.

Click here to obtain the Fox News app

In addition, most of the study participants were obese and diabetic, which means that the results may not be applicable to all patients with suppurativa idradenitis.

“Future randomized trials are necessary to determine who will benefit the most and to establish safety and efficiency in the larger HS population,” said Camp.

“GLP-1 therapies remain investigation for the hidradenitis and are not an approved indication.”

The dermatologist does not currently recommend GLP-1 only for hidradenitis or other skin conditions.

“SH patients should know that if these results hope-showing improvements in severity, frequency of thrusts, pain and quality of life during the months of treatment-GLP-1 therapies remain students for HS and are not an approved indication,” he noted.

For more health items, visit Foxnews.com/health

However, those that are eligible for the treatment of GLP-1 for diabetes or obesity can see that these drugs offer “an additional potential advantage of improving SH symptoms”.

“Introductory initiation without clear indication must be approached with caution – the cost of weighing, the side effects and the lack of proof of final trials – and only under the direction of a dermatologist and a prescription supplier,” added Camp.